

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/00205 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2004/016126

(22) International Filing Date: 20 May 2004 (20.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/474,964 2 June 2003 (02.06.2003) US
60/475,642 4 June 2003 (04.06.2003) US
60/478,648 1 August 2003 (01.08.2003) US
60/564,636 22 April 2004 (22.04.2004) US
60/566,869 30 April 2004 (30.04.2004) US

(71) Applicants (for all designated States except US):
SAMARITAN PHARMACEUTICALS [US/US]; 101

Convention Center Drive, Las Vegas, NV 89109 (US).
GEORGETOWN UNIVERSITY [US/US]; Office of
Technology Licensing, Box 571408, Washington, DC
20057-1408 (US).


(71) Applicants and
(72) Inventors: **LECANU, Laurent** [FR/US]; 8370 Greensbo
Drive, Building #4, Apt. 706, McLean, VA 22102 (US).
GREESON, Janet [US/US]; 2877 Paradise Road, Suite
801, Las Vegas, NV 89109 (US). **PAPADOPOULOS, Vas-
silius** [US/US]; 15417 Peach Leaf Drive, North Potomac,
MD 20878 (US). **XU, Jing** [CN/US]; 14911 Forest Land-
ing Circle, Rockville, MD 20850 (US).

(74) Agents: **STEFFEY, Charles, E.** et al.; Schwegman, Lund-
berg, Woessner & Kluth, P.A., P.O. Box 2938, Minneapolis,
MN 55402 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

[Continued on next page]


(54) Title: METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS




Procaine




SP010



SP014



SP016



SP017

(57) Abstract: The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome.

WO 2005/00205 A2